Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
R8-liposome-BCG-CWS
- Development stage
- Preclinical
- Lead developer
- Hokkaido University
- Modality
- Nanoparticles → Drug Delivery Systems
- Administration
- Intravesical
01
Overview
**R8-liposome-BCG-CWS** is an investigational, non-live BCG-derived intravesical cancer immunotherapy formulation for bladder cancer. It encapsulates *Mycobacterium bovis* bacillus Calmette-Guérin cell wall skeleton in liposomes functionalized with octaarginine, a cell-penetrating peptide intended to improve intracellular delivery into urothelial tumor cells. In preclinical bladder-cancer models, it inhibited BBN-induced rat bladder carcinogenesis and increased expression of NKG2D ligands including MICB and ULBP1 on human bladder-cancer cells, increasing their susceptibility to lymphokine-activated killer-cell cytolysis.
- Other names
- octaarginine-modified liposomes incorporating bacillus Calmette-Guérin cell wall skeletonR8-liposome-bacillus Calmette-Guérin-cell wall skeletonR8-liposome-BCG-CWR-8-liposome-BCG-CWR 8-liposome-BCG-CWR8-liposome-BCG-CWSR-8-liposome-BCG-CWSR 8-liposome-BCG-CWS
02
Targets
TLR2 (Toll-like Receptor 2)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on R8-liposome-BCG-CWS.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on R8-liposome-BCG-CWS.